Astria Therapeutics Presents Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit
-- Substantial Need to Decrease
-- Findings Suggest Patients Are Interested in Trying New Therapies that Offer Similar Efficacy and Less Frequent Dosing --
“Our learnings from these findings support that there is a substantial need for new HAE treatments, and that HAE patients are open to trying new therapies that could reduce their disease and treatment burdens,” said
The findings came from interviews of ten HAE patients using a structured one-hour interview guide. Patients were screened for inclusion based on self-identified disease type (HAE Types 1 and 2), disease severity (moderate or severe when not on treatment), and eligibility for prophylactic treatment. Interviews covered lifetime experiences with diagnosis, disease and treatment management, advocacy, and perceptions of hypothetical improvements in preventative therapy.
The findings suggest that HAE patients are seeking to reduce their treatment burden as much as their disease burden and may be open to trying new therapies that can address these needs. On average, patients tried two to three preventative treatments, most often switching for more convenient administration. Additionally, despite being on preventative treatment, half of the patients interviewed think about future attacks often or always. All patients shared that they would be compelled to switch from their current therapy if a new therapy offered similar efficacy with less frequent dosing.
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of applicable securities laws and regulations including, but not limited to, statements regarding: the potential attributes and differentiated profile of STAR-0215 as a treatment for HAE; and the need for additional treatments for HAE. The use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “goals,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on the Company’s current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, future financial performance, results of pre-clinical and clinical results of the Company’s product candidates and other future conditions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties: related to changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors, including the COVID-19 pandemic; risks inherent in pharmaceutical research and development, such as: adverse results in our drug discovery, preclinical and clinical development activities, the risk that the results of pre-clinical studies may not be replicated in clinical studies, the Company’s ability to enroll patients in our clinical trials, and the risk that any of the Company’s clinical trials may not commence, continue or be completed on time, or at all; decisions made by, or feedback received from, the